Bacterial meningitis vaccines: Not just for kids

Current Infectious Disease Reports

Volumn 11, Issue 4, 2009, Pages 302-308

  Verma, Renuka ^a   Fisher, Margaret C ^a  

^a MONMOUTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CEFTRIAXONE; CIPROFLOXACIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCAL C DIPHTHERIA TOXOID CONJUGATED VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PENICILLIN G; PENTACEL; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; RIFAMPICIN; TETANUS TOXOID; TRIHIBIT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; BACTERIAL MENINGITIS; CELLULAR IMMUNITY; CLINICAL TRIAL; DIPHTHERIA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDEMIC DISEASE; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INCIDENCE; INFLUENZA; LOW DRUG DOSE; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NEISSERIA MENINGITIDIS; NONHUMAN; PATHOPHYSIOLOGY; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TETANUS;

EID: 67649086106     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0045-z     Document Type: Review

References (49)

1. Wenger JD, Hightower AW, Facklam RR, et al.: Bacterial meningitis in the United States, 1986: Report of a multistate surveillance study. J Infect Dis 1990, 162:1316-1323.
2. Swartz MN: Bacterial meningitis - a view of the past 90 years. N Engl J Med 2004, 351:1826-1828.
3. Schuchat A, Robinson K, Wenger JD, et al.: Bacterial meningitis in the United States in 1995. N Engl J Med 1997, 337:970-976.
4. Wenger JD: Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada (Haemophilus influenzae type b disease and vaccination: The west). Pediatr Infect Dis 1998, 17:132-136.
5. Peltola H, Kayhty H, Sivonen A, et al.: Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977, 60:730-737.
6. Peltola H, Kayhty H, Virtane M, et al.: Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984, 310:1561-1566.
7. Heath PT: Haemophilus influenzae type b Conjugate Vaccines: A review of Efficacy Data (Haemophilus influenzae type B Vaccines). Pediatr Infect Dis 1998, 17:S117-S122.
8. Santosham M, Wolff M, Reid R, et al.: The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991, 324:1767-1772.
9. Ward J, Brenneman G, Letson GW, et al.: Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med 1990, 323:1393-1401.
10. Eskola J, Ward J, Dagan R, et al.: Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999, 354:2063-2068.
11. Pichichero M, Latiolais T, Bernstein D, et al.: Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four-, and six-month-old infants (original studies). Pediatr Infect Dis 1997, 16:863-870.
12. Goldblatt D, Richmond P, Millard E, et al.: The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J Infect Dis 1999, 180:538-541.
13. Granoff DM: Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin Infect Dis 2001, 33(Suppl 4):S278-S287.
14. Schmitt HJ, Vonkries R, Hassenpflug B, et al.: Haemophilus influenzae type b disease: Impact and effectiveness of Diphtheria-tetanus toxoid-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J 2001, 20:767-774.
15. McConnell A, Tan B, Scheifele D, et al.: Invasive infections caused by Haemophilus influenzae serotypes in twelve Canadian IMPACT centers,1996-2001. Pediatr Infect Dis J 2007, 26:1025-1103.
16. Scheifele DW, Bettinger JA, Halperin SA, et al.: Ongoing Control of Haemophilus influenzae Type b Infections in Canadian Children, 2004-2007. Pediatr Infect Dis J 2008, 27:755-757.
17. Galil K, Singleton R, Levine OS, et al.: Reemergence of invasive Haemophilus influenzae type B disease in a well-vaccinated population in remote Alaska. J Infect Dis 1999, 179:101-106.
18. Centers for Disease Control and Prevention: National, state, and local area vaccination coverage among children aged 19-35 months - United States, 2006. MMWR Morb Mortal Wkly Rep 2007, 56: 880-885.
19. Takala AK, Eskola J, Leinone M, et al.: Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugated vaccine. J Infect Dis 1991, 164:982-986.
20. Murphy TV, Pastor P, Medley F, et al.: Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr 1993, 122:517-523.
21. American Academy of Pediatrics: Summaries of infectious diseases. In Red Book: 2006 Report of the Committee on Infectious Diseases, edn 27. Edited by Pickering LK, Baker CJ, Long SS, McMillan JA. Elk Grove Village, IL: American Academy of Pediatrics; 2006:314-318.
22. Centers for Disease Control and Prevention: Interim recommendations for the use of Haemophilus influenzae type b (Hib) conjugate vaccines related to the recall of certain lots of Hib-containing vaccines (PedvaxHIB and Comvax). MMWR 2007, 56: 1318-1320.
23. Black S, Shinefield H, Fireman B, et al.: Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19:187-195.
24. Whitney CG, Farley MM, Hadler J, et al.: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
25. Jackson LA, Neuzil KM, Yu O, et al.: Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003, 348:1747-1755.
26. Tsai CJ, Griffin MR, Nuorti P, et al.: Changing epidemiology of pneumococcal meningitis after the introduction of Pneumococcal conjugate vaccine in the United States. Clin Infect Dis 2008, 46:1664-1672.
27. Kyaw MH, Lynfield R, Schaffner W, et al.: Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006, 354:1455-1463.
28. Bender JM, Ampofo K, Korgenski K, et al.: Pneumococcal necrotizing pneumonia in Utah: Does serotype matter? Clin Infect Dis 2008, 46:1346-1352.
29. Hsu HE, Shutt KA, Moore MR, et al.: Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360;244-256.
30. Dagan R, Givon-Lavi N, Zamir O, et al.: Efect of a nonvalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 2003, 22:532-539.
31. Givon-Lavi N, Fraser D, Dagan R: Vaccination of daycare center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J 2003, 22:524-531.
32. American Academy of Pediatrics: Summaries of infectious diseases. In Red Book: 2006 Report of the Committee on Infectious Diseases, edn 27. Edited by Pickering LK, Baker CJ, Long SS, McMillan JA. Elk Grove Village, IL: American Academy of Pediatrics; 2006:532-536.
33. Pollard AJ, Levine M: Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 2000, 19:333-345.
34. Centers for Disease Control and Prevention: Meningococcal disease and college students: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000, 49(RR-7):13-20.
35. Rosenstein NE, Perkins BA, Stephens DS, et al.: The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999, 180:1894-1901.
36. Campagne G, Garba A, Fabre P, et al.: Safety and immunogenicity of three doses of a Neisseria meningitidis A+C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000, 19:144-150.
37. Richmond P, Borrow R, Miller E, et al.: Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999, 179:1569-1572.
38. Granoff DM, Pollard AJ: Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007, 26:716-722.
39. Pichichero M, Casey J, Blatter M, et al.: Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two-to ten-year-old children. Pediatr Infect Dis J 2005, 24:57-62.
40. Rennels M, King J Jr, Ryall R, et al.: Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004, 23:429-435.
41. Tejedor JC, Moro M, Merino JM, et al.: Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months. Pediatr Infect Dis J 2008, 27:579-588.
42. Vu DM, Welsch JA, Zuno-Mitchell P, et al.: Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006, 193:821-828.
43. Ortega-Sanchez IR, Meltzer MI, Shepard C, et al.: Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis 2008, 46:1-13.
44. Centers for Disease Control and Prevention: Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR 2008, 57:1100-1103.
45. Centers for Disease Control and Prevention: Recommended immunization schedules for persons aged 0 through 18 Years - United States, 2009. MMWR 2009, 57(51):Q1-Q4.
46. Centers for Disease Control and Prevention: Recommended adult immunization schedule - United States, 2009. MMWR 2009, 57(53):Q1-Q4.
47. American Academy of Pediatrics: Summaries of infectious diseases. In Red Book: 2006 Report of the Committee on Infectious Diseases, edn 27. Edited by Pickering LK, Baker CJ, Long SS, McMillan JA. Elk Grove Village, IL: American Academy of Pediatrics; 2006:312-314, 455-457, 536-537.
48. Schaad UB: Chemoprophylaxis of bacterial meningitis. J Antimicrob Chemother 1985, 15:131-133.
49. Centers for Disease Control and Prevention: Emergence of fluoroquinolone-resistant Neisseria meningitidis - Minnesota and North Dakota, 2007-2008. MMWR Morb Mortal Wkly Rep 2008, 57:173-175.